Vivoryon Therapeutics N.V. to Report Q1 2026 Financial Results on June 11, 2026

Rhea-AI Summary

Vivoryon Therapeutics (VVY), a clinical-stage company developing small molecule medicines for inflammatory and fibrotic disorders focused on kidney diseases, will publish its Q1 2026 financial results for the period ended March 31, 2026 on Thursday, June 11, 2026.

The next financial and business update conference call/webcast is planned with the H1 2026 results, anticipated in August.

Market Context

This announcement set the timetable for Vivoryon’s Q1 2026 financial results for the period ended Ma...

Analysis

This announcement set the timetable for Vivoryon’s Q1 2026 financial results for the period ended March 31, 2026, to be published on June 11, 2026. As a clinical-stage company focused on inflammatory and fibrotic kidney diseases, the upcoming report and subsequent H1 update will be important for clarity on cash position, development priorities, and runway. Investors may watch those future disclosures for concrete figures on spending, liquidity, and progress in the pipeline.

Key Figures

Q1 2026 period end: March 31, 2026 Q1 2026 release date: June 11, 2026

2 metrics

Q1 2026 period end March 31, 2026 Quarter ended date for upcoming report

Q1 2026 release date June 11, 2026 Scheduled publication of Q1 2026 financial results

Key Terms

small molecule, fibrotic disorders, kidney diseases

3 terms

small molecule medical

"a clinical stage company developing small molecule medicines for inflammatory"

A small molecule is a low-weight chemical compound that can enter cells easily and interact with specific proteins or biological pathways to change how they work, much like a small key fitting into a lock. Investors care because small molecules are a common and often faster route to develop medicines, can be manufactured at scale, and may offer clearer regulatory and commercial paths compared with larger biologic therapies, affecting potential costs, timelines and returns.

fibrotic disorders medical

"developing small molecule medicines for inflammatory and fibrotic disorders, with"

Chronic conditions in which organs or tissues develop excess scar-like material that thickens and stiffens them, reducing their ability to function properly—examples include lungs, liver, heart, and skin. Investors should care because these disorders often lack effective treatments, create long-term healthcare costs, and drive demand for new drugs, diagnostics, and medical devices; think of it like internal scarring that slowly locks an organ in place, creating sizable market opportunities for successful therapies.

kidney diseases medical

"fibrotic disorders, with a primary focus on kidney diseases, today announced"

Kidney diseases are a set of medical conditions that harm the kidneys’ ability to filter waste and balance fluids and salts, ranging from sudden injuries to long‑term decline. For investors, they matter because they define patient populations, treatment needs, regulatory hurdles and potential revenue for drugs, devices and diagnostics—think of the kidneys as a car’s filter: when it fails, repair or replacement products and ongoing care become big-cost, high-demand markets.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Vivoryon Therapeutics N.V. to Report Q1 2026 Financial Results
on June 11, 2026

Halle (Saale) / Munich, Germany, June 8, 2026 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company developing small molecule medicines for inflammatory and fibrotic disorders, with a primary focus on kidney diseases, today announced that it will publish its first quarter financial results for the period ended March 31, 2026 on Thursday, June 11, 2026.

The Company’s next financial and business update conference call / webcast will be held in conjunction with the publication of its H1 results, anticipated in August.  

###

About Vivoryon Therapeutics N.V.
Vivoryon is a clinical stage biotechnology company focused on developing innovative small molecule-based medicines for the treatment of inflammatory and fibrotic disorders of the kidney. Driven by its passion for ground-breaking science and innovation, the Company strives to improve patient outcomes by changing the course of severe diseases through modulating the activity and stability of pathologically relevant proteins. Vivoryon’s most advanced program, varoglutamstat, a proprietary, first-in-class orally available QPCT/L inhibitor, is being evaluated to treat diabetic kidney disease. www.vivoryon.com

Vivoryon Forward Looking Statements
This press release includes forward-looking statements, including, without limitation, those regarding the business strategy, management plans and objectives for future operations of Vivoryon Therapeutics N.V. (the “Company”), estimates and projections with respect to the market for the Company’s products and forecasts and statements as to when the Company’s products may be available. Words such as “anticipate,” “believe,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,” “project,” “predict,” “should” and “will” and similar expressions as they relate to the Company are intended to identify such forward-looking statements. These forward-looking statements are not guarantees of future performance; rather they are based on the Management’s current expectations and assumptions about future events and trends, the economy and other future conditions. The forward-looking statements involve a number of known and unknown risks and uncertainties. These risks and uncertainties and other factors could materially adversely affect the outcome and financial effects of the plans and events described herein. The Company’s results of operations, cash needs, financial condition, liquidity, prospects, future transactions, strategies or events may differ materially from those expressed or implied in such forward-looking statements and from expectations. As a result, no undue reliance should be placed on such forward-looking statements. This press release does not contain risk factors. Certain risk factors that may affect the Company’s future financial results are discussed in the published annual financial statements of the Company. This press release, including any forward-looking statements, speaks only as of the date of this press release. The Company does not assume any obligation to update any information or forward-looking statements contained herein, save for any information required to be disclosed by law.

For more information, please contact:

Vivoryon Therapeutics N.V.
Dr. Manuela Bader, Director IR & Communication
Email: IR@vivoryon.com

LifeSci Advisors
Sandya von der Weid
Tel: +41 78 680 05 38
Email: svonderweid@lifesciadvisors.com  

Attachment

• 20260608_Q1 2026 NoR

FAQ

When will Vivoryon Therapeutics (VVY) report its Q1 2026 financial results?

Vivoryon Therapeutics will publish its Q1 2026 financial results on Thursday, June 11, 2026. According to Vivoryon, the report covers the quarter ended March 31, 2026, and will provide updated financial information for investors and stakeholders.

What period does Vivoryon Therapeutics' Q1 2026 financial report (VVY) cover?

Vivoryon’s Q1 2026 financial report covers the period ended March 31, 2026. According to Vivoryon, the company will release these first quarter figures on June 11, 2026, giving investors insight into its early 2026 financial performance.

Will Vivoryon Therapeutics (VVY) hold a conference call for Q1 2026 results?

Vivoryon will not hold a separate conference call specifically for Q1 2026 results. According to Vivoryon, the next financial and business update call/webcast will occur together with publication of H1 2026 results, which is anticipated in August.

When is Vivoryon Therapeutics’ next financial and business update conference call for VVY?

Vivoryon’s next financial and business update conference call/webcast is expected in August, alongside H1 2026 results. According to Vivoryon, this event will follow the earlier publication of Q1 2026 financial figures on June 11, 2026.

What type of company is Vivoryon Therapeutics (VVY) that is reporting Q1 2026 results?

Vivoryon Therapeutics is a clinical-stage company developing small molecule medicines for inflammatory and fibrotic disorders. According to Vivoryon, its primary focus is on kidney diseases, and it is listed on Euronext Amsterdam under the ticker symbol VVY.

Where is Vivoryon Therapeutics (VVY) based while preparing its Q1 2026 report?

Vivoryon Therapeutics is based in Halle (Saale) and Munich, Germany. According to Vivoryon, the company plans to publish its Q1 2026 financial results on June 11, 2026, followed by an H1 2026 update and conference call anticipated in August.